Big data specialists could breathe life into the pharma sector
Increased hiring of big data experts and data scientists could help to revitalise the pharmaceutical sector, according to NonStop Recruitment.
An analysis by the pharmaceutical recruitment specialists found that a greater focus on exploiting data could drive greater efficiency which would benefit the entire sector. The price of developing new drugs has risen to prohibitive levels with the failure of late stage clinical trials often costing firms millions. NonStop has argued that hiring big data specialists could mean that the data from these trials is more effectively exploited.
Abid Kanji, Associate Director of NonStop Recruitment, comments: “As we all know, the process of getting a new drug to market is a long and costly one. Firms produce enormous amounts of data from trials and testing, but currently use it very inefficiently. Taking on larger numbers of data scientists and big data experts could mean that organisations can exploit the data more effectively and then save costs further down the line when it comes to drug development. This isn’t reinventing the wheel. It’s a relatively simple solution to an obvious problem that is causing massive wastage. The data can be used to help direct research more efficiently and could reduce the amount of time that firms spend pursuing unviable opportunities. The process would start with sharing information internally, but eventually the entire sector could reap the benefits.”
“The pharmaceutical industry arrived somewhat late to the ‘big data revolution’ and with the sector in such a tumultuous state it seems clear that firms should be doing all they can to become more efficient. They don’t even need to take on an expert with extensive direct experience in the pharmaceutical sector, firms simply require specialists who understand how to break down and analyse data to spot areas where their employers could improve efficiency. This could be a significant opportunity for the entire industry and it’s one that we hope they will adopt.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance